Synthesis and Evaluation of a Monomethyl Auristatin E─Integrin α<sub>v</sub>β<sub>6</sub> Binding Peptide–Drug Conjugate for Tumor Targeted Drug Delivery-Reference-Cited by-同舟云学术

Synthesis and Evaluation of a Monomethyl Auristatin E─Integrin α_vβ₆ Binding Peptide–Drug Conjugate for Tumor Targeted Drug Delivery

Published:2023-07-07 Issue:14 Volume:66 Page:9842-9852
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Davis Ryan A.¹^ORCID,Ganguly Tanushree¹^ORCID,Harris Rebecca²,Hausner Sven H.²,Kovacs Luciana²,Sutcliffe Julie L.¹²³⁴

Affiliation:

1. Department of Biomedical Engineering, University of California, Davis, One Shields Avenue, Davis, California 95616, United States

2. Department of Internal Medicine, Division of Hematology/Oncology, University of California, Davis, 4150 V Street, Sacramento, California 95817, United States

3. Center for Molecular and Genomic Imaging, University of California, Davis, 451 Health Sciences Drive, Davis, California 95616, United States

4. Radiochemistry Research and Training Facility, University of California, Davis, 2921 Stockton Blvd., Suite 1760, Sacramento, California 95817, United States

Funder

National Institutes of Health

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00631

Reference51 articles.

1. On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site

2. Antibody-drug conjugates—an emerging class of cancer treatment

3. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates